Related Experiment Videos
Osteosarcoma
1Department of Pediatric Hematology and Oncology, Children's University Hospital, Hamburg, Germany.
Abstract:
Findings from molecular genetic and cytogenetic investigations suggest that mutations in suppressor genes play a key role in osteosarcoma pathogenesis. RB and p53 are frequently involved and are speculated to be indispensable components. Alterations in putative suppressor genes on chromosomes 18q and 3q additionally may be involved in various patterns. The high resolution of magnetic resonance imaging in osteosarcoma imaging is confirmed, and the validity of dynamic gadolinium-enhanced imaging for estimation of tumor response is stated. The efficacy of single-drug high-dose methotrexate convincingly is shown to be 19%. Phase II trials with nonspecific immunostimulation using a synthetic liposomal mycobacterium-derived antigen (liposomal muramyl tripeptide phosphatidylethanolamine) do not yet allow us to draw conclusions on eventual efficacy. A novel and promising approach may be intervention in the endocrine or orthocrine and paracrine tumor growth regulation. Hypophysectomy in mice dramatically reduced plasma or insulin-like growth factor and local as well as systemic growth of transplanted osteosarcoma. The close interrelation between tumor response, surgical margins, and local control is demonstrated, as well as the fatal prognosis after local failure. Also, the validity of known risk factors in patients undergoing intensive chemotherapy has been confirmed. Interestingly, dose intensity was not found to influence prognosis.
Insights
Genetic mutations in suppressor genes are key to osteosarcoma. Research confirms MRI effectiveness, highlights methotrexate
Area of Science:
- Oncology
- Molecular Genetics
- Medical Imaging
Background:
- Osteosarcoma pathogenesis involves suppressor gene mutations, notably RB and p53.
- Alterations in genes on chromosomes 18q and 3q may also contribute.
- Tumor growth regulation pathways present novel therapeutic targets.
Purpose of the Study:
- To review current findings on osteosarcoma genetics, imaging, and treatment efficacy.
- To evaluate novel therapeutic strategies targeting tumor growth regulation.
- To assess the impact of risk factors and treatment intensity on prognosis.
Main Methods:
- Molecular genetic and cytogenetic investigations.
- Magnetic resonance imaging (MRI) and dynamic gadolinium-enhanced imaging.
- Review of clinical trial data for chemotherapy and immunotherapy.
- Preclinical studies involving hypophysectomy in mice.
Main Results:
- RB and p53 mutations are frequently implicated in osteosarcoma.
- High-resolution MRI and dynamic contrast-enhanced MRI are effective for imaging and response assessment.
- High-dose methotrexate shows 19% efficacy; immunotherapy results are inconclusive.
- Intervention in growth factor pathways (e.g., IGF) shows promise in preclinical models.
- Tumor response, surgical margins, and local control are critical for prognosis.
- Known risk factors are confirmed; dose intensity did not impact prognosis.
Conclusions:
- Genetic mutations, particularly in suppressor genes, are central to osteosarcoma development.
- Advanced imaging techniques are vital for diagnosis and treatment monitoring.
- Targeting tumor growth regulation pathways offers a promising therapeutic avenue.
- Effective local control and management of risk factors are crucial for patient outcomes.